Infectious disease
In addition to coming sooner than expected, the results are even better than expected. The trial hit all primary efficacy endpoints.
We have known since early on that diabetes is a complicating risk factor for developing severe illness from the SARS-CoV-2 virus that causes COVID-19. The hypothesis is now being floated by members of the medical community that COVID-19 may cause the disease to return – or potentially a unique version of it.
Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global COVID-19 pandemic.
There are similarities between the two COVID-19 vaccine candidates, and a few differences. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 17, 2020.
Johnson & Johnson secured more than $1 billion in additional funding for its COVID-19 vaccine research through an expansion of its partnership with the Biomedical Advanced Research and Development Authority.
Only a week after Pfizer and BioNTech’s preliminary data readout of its COVID-19 vaccine suggested a 90% efficacy rate, Moderna reported interim efficacy data for its vaccine of 94.5%.
The BioNTech scientist said his vaccine can “bash the virus over the head”.
It was a particularly busy week for clinical trial updates, mostly because of several virtual conferences, including the virtual American Heart Association Scientific Sessions 2020 and The Society for Immunotherapy of Cancer’s Annual Meetings. Here’s a look.
Synairgen announced today that its data from the SG016 trial was published in the journal The Lancet Respiratory Medicine. The trial, which included 101 hospitalized COVID-19 patients, looked at SNG001 as a potential treatment.
PRESS RELEASES